Literature DB >> 34995041

Expression of ectopic heat shock protein 90 in male and female primary afferent nociceptors regulates inflammatory pain.

Yaomin Wang1, Scott A Scarneo1,2, Shin Hyung Kim1,3, Xin Zhang1, Jiegen Chen1, Kelly W Yang2, Philip Hughes2, Timothy Haystead2, Andrea G Nackley1,2.   

Abstract

ABSTRACT: Heat shock protein 90 (Hsp90) is a ubiquitously expressed integral cellular protein essential for regulating proteomic stress. Previous research has shown that Hsp90 regulates critical signaling pathways underlying chronic pain and inflammation. Recent discovery of membrane bound ectopic Hsp90 (eHsp90) on tumor cells has shown that Hsp90 induction to the plasma membrane can stabilize disease-relevant proteins. Here, we characterize eHsp90 expression in a mouse model of inflammation and demonstrate its role in nociception and pain. We found that intraplantar complete Freund adjuvant (CFA) induced robust expression of eHsp90 on the cell membranes of primary afferent nociceptors located in the L3-L5 dorsal root ganglia (DRG), bilaterally, with minimal to no expression in other tissues. Complete Freund adjuvant-induced increases in eHsp90 expression on lumbar DRG were significantly greater in females compared with males. Furthermore, exogenous Hsp90 applied to primary Pirt-GCaMP3 nociceptors induced increases in calcium responses. Responses were estrogen-dependent such that greater activity was observed in female or estrogen-primed male nociceptors compared with unprimed male nociceptors. Treatment of mice with the selective eHsp90 inhibitor HS-131 (10 nmol) significantly reversed CFA-induced mechanical pain, thermal heat pain, and hind paw edema. Notably, a higher dose (20 nmol) of HS-131 was required to achieve analgesic and anti-inflammatory effects in females. Here, we provide the first demonstration that inflammation leads to an upregulation of eHsp90 on DRG nociceptors in a sex-dependent manner and that inhibition of eHsp90 reduces nociceptor activity, pain, and inflammation. Thus, eHsp90 represents a novel therapeutic axis for the development of gender-tailored treatments for inflammatory pain.
Copyright © 2021 International Association for the Study of Pain.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34995041      PMCID: PMC9001751          DOI: 10.1097/j.pain.0000000000002511

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   7.926


  41 in total

1.  The relationship of sex and clinical pain to experimental pain responses.

Authors:  Roger B Fillingim; Robert R Edwards; Tykeysha Powell
Journal:  Pain       Date:  1999-12       Impact factor: 6.961

Review 2.  Structure and mechanism of the Hsp90 molecular chaperone machinery.

Authors:  Laurence H Pearl; Chrisostomos Prodromou
Journal:  Annu Rev Biochem       Date:  2006       Impact factor: 23.643

3.  Hsp90 chaperones protein folding in vitro.

Authors:  H Wiech; J Buchner; R Zimmermann; U Jakob
Journal:  Nature       Date:  1992-07-09       Impact factor: 49.962

4.  Models of inflammation: Carrageenan- or complete Freund's Adjuvant (CFA)-induced edema and hypersensitivity in the rat.

Authors:  Jill C Fehrenbacher; Michael R Vasko; Djane B Duarte
Journal:  Curr Protoc Pharmacol       Date:  2012-03

5.  Ethical guidelines for investigations of experimental pain in conscious animals.

Authors:  Manfred Zimmermann
Journal:  Pain       Date:  1983-06       Impact factor: 6.961

6.  Induction of Hsp90 protein expression in malignant melanomas and melanoma metastases.

Authors:  B Becker; G Multhoff; B Farkas; P-J Wild; M Landthaler; W Stolz; T Vogt
Journal:  Exp Dermatol       Date:  2004-01       Impact factor: 3.960

7.  Evidence for a role of heat shock protein-90 in toll like receptor 4 mediated pain enhancement in rats.

Authors:  M R Hutchinson; K M Ramos; L C Loram; J Wieseler; P W Sholar; J J Kearney; M T Lewis; N Y Crysdale; Y Zhang; J A Harrison; S F Maier; K C Rice; L R Watkins
Journal:  Neuroscience       Date:  2009-09-27       Impact factor: 3.590

8.  Transforming growth factor alpha (TGFalpha)-stimulated secretion of HSP90alpha: using the receptor LRP-1/CD91 to promote human skin cell migration against a TGFbeta-rich environment during wound healing.

Authors:  Chieh-Fang Cheng; Jianhua Fan; Mark Fedesco; Shengxi Guan; Yong Li; Balaji Bandyopadhyay; Alexandra M Bright; Dalia Yerushalmi; Mengmeng Liang; Mei Chen; Yuan-Ping Han; David T Woodley; Wei Li
Journal:  Mol Cell Biol       Date:  2008-03-10       Impact factor: 4.272

9.  Small molecule inhibitors of Hsp90 potently affect inflammatory disease pathways and exhibit activity in models of rheumatoid arthritis.

Authors:  John W Rice; James M Veal; R Patrick Fadden; Amy F Barabasz; Jeffrey M Partridge; Thomas E Barta; Laura G Dubois; Kenneth H Huang; Sarah R Mabbett; Melanie A Silinski; Paul M Steed; Steven E Hall
Journal:  Arthritis Rheum       Date:  2008-12

10.  Inhibiting heat-shock protein 90 reverses sensory hypoalgesia in diabetic mice.

Authors:  Michael J Urban; Chengyuan Li; Cuijuan Yu; Yuanming Lu; Joanna M Krise; Michelle P McIntosh; Roger A Rajewski; Brian S J Blagg; Rick T Dobrowsky
Journal:  ASN Neuro       Date:  2010-08-11       Impact factor: 4.146

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.